Alnylam Pharmaceuticals (ALNY) Total Debt (2016 - 2025)

Alnylam Pharmaceuticals posted quarterly Total Debt of $121.3 million for Q3 2025, little changed on a QoQ basis from $120.8 million in Q2 2025.

Alnylam Pharmaceuticals (ALNY) has 8 years of Total Debt data on file, last reported at $121.3 million in Q3 2025.

For the quarter ending Q3 2025, Total Debt changed N/A year-over-year to $121.3 million; the trailing twelve-month figure through Sep 2025 stood at $121.3 million (changed N/A YoY), and the FY2024 full-year result was $93.8 million, changed N/A from the prior year.
Total Debt for Q3 2025 stood at $121.3 million, roughly flat from $120.8 million in the prior quarter.
Across five years, Total Debt topped out at $675.7 million in Q4 2021 and bottomed at $93.8 million in Q4 2024.
The 3-year median for Total Debt is $120.8 million (2025), against an average of $225.9 million.
Peak annual rise in Total Debt reached 253.25% in 2021, while the deepest fall reached 253.25% in 2021.
A 3-year view of Total Debt shows it stood at $675.7 million in 2021, then plunged by 86.12% to $93.8 million in 2024, then advanced by 29.32% to $121.3 million in 2025.
The last three Total Debt figures came in at $121.3 million (Q3 2025), $120.8 million (Q2 2025), and $118.1 million (Q1 2025), per Business Quant data.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	319.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	110.96 Mn
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	-
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	1.99 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	-
10	Revolution Medicines	32.39 Bn	32.39 Bn	-	-

Download Data 🔒